- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04614766
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3)
A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
Azedra and Lutatheraare are FDA-approved radioactive drugs designed to treat specific tumor cells. These drugs are a combination of the radiation (131-Iodine, 177-lutetium) and a protein that targets the tumor cell (MIBG or DOTATATE). Because these proteins are attracted to, and stick to, the tumor, the radiation is centered in the tumors. This kills more tumor cells and minimizes radiation-damage to healthy tissues, like the heart and lungs.
Two organs still absorb some of the radiation, though: bone marrow and the kidney. These organs limit how much radiation can be given to tumors, but we don't know how much radiation is too much. Too much radiation to bone marrow can result in anemia. Too much radiation to the kidneys can result in kidney failure. From prior radiation therapies, we have a general idea of how much radiation we can give safely.
Azedra and Lutathera have never been given together. We want to give them together because many times, tumors are actually groups of different types of cells. This means, not all the cells respond to therapy the same way. If some tumor cells survive therapy, the tumor will continue to grow and eventually come back. We know some mid-gut neuroendocrine tumors (NETs) have targets for DOTATATE and some other mid-gut NETs have targets for MIBG. We also have now identified that some people with mid-gut NETs have different tumors: some with targets for MIBG and some with targets for DOTATATE. For these people, this means treating only with Azedra or Lutathera will not be enough to treat their cancer. They need both radioactive drugs.
Because we are combining these radioactive drugs, this study is known as a first-in-man study. We are also using a special imaging to help us estimate the radiation dose to the bone marrow and to the kidneys. This is what decides the final dose of Azedra and Lutathera.
After receiving a standard treatment of Lutathera, participants are asked to undergo imaging to verify they have both MIBG and DOTATATE tumor types:
- participants are given a tracer dose of Azedra
- a special camera (SPECT/CT) collects images (scans)
- imaging (scans) are done over 4 calendar days
- blood samples are taken at that time, too, to measure the circulating amount of tracer doses
If the scans show a participant does not have both MIBG and DOTATATE receptors, they continue with standard therapy (Lutathera only). Participants are asked to still undergo study assessments to provide a comparison group.
If the scans show a participant has both MIBG and DOTATATE receptors, combined therapy is administered:
- a customized dose of Lutathera is given on day 1 of a treatment cycle. This is given outpatient.
- a customized dose of Azedra is given on day 2 of a treatment cycle. This is given inpatient (admitted to the hospital).
- participants are monitored through blood tests to identify the side effects of therapy.
Each participant can have up to 2 cycles of therapy. The cycles are 12 weeks apart.
The doses for Lutathera and Azedra are decided based on radiation to the bone marrow and radiation to the kidney. Doses are decided by how well other participants have done on this study.
Participants have life long follow-up for this study. This is very important, because a study like this has not been done.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- Holden Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to understand and willingness to provide informed consent; legally authorized representative will not be utilized compliant with the principles of good clinical practice (i.e., ICH E6(R2)).
- Stated willingness to comply with all study procedures and availability for duration of study
- Aged ≥ 18 years to 80 years at the time of study drug administration
Pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be:
- a well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2) with a primary tumor location believed to be midgut, or,
- pheochromocytoma, or,
- paraganglioma
- Recommended to receive LUTATHERA® or AZEDRA® therapy
- Disease measuring ≥ 1.5 cm in diameter on CT or MRI as measured per RECIST
- Adequate performance status (ECOG of 0 or 1; or KPS of >70).
- Agrees to contraception during therapy.
- Agreement to adhere to Lifestyle Considerations throughout study duration
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Patient with increased fall risk in the opinion of healthcare professionals
- Women who are pregnant.
- Women who are breast feeding.
- Surgery, radiation therapy, or chemotherapy ≤ 4 weeks of C1D1. (Toxicities from prior therapies should have resolved to ≤ CTCAE grade 1 or a new baseline established).
- Prior peptide-receptor radiotherapy (PRRT).
- Therapeutic investigational drug within 4 weeks of C1D1 (imaging agents are acceptable).
- A concurrent malignancy that, in the opinion of the investigator, would cause a safety risk by delaying therapy or confound/negatively impact study objectives (documentation of the rationale must be provided).
- History of congestive heart failure with a history of cardiac ejection fraction ≤ 35%.
- Patients unable to discontinue medications known to affect MIBG uptake (unless approved by the PI or designee)
- Proteinuria grade 2 (i.e., 2+ proteinuria).
- Prior external beam radiation dose of >16 Gy to the kidneys.
- Prior external beam radiation (including brachytherapy) involving 25% of the bone marrow (excluding scatter doses of 5 Gy) as estimated by a radiation oncologist.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Octreoscan® or Netspot™.
Participants meeting the above criteria will receive one cycle of standard Lutathera treatment (200 millicuries) as well as a tracer dose of Azedra for imaging. Participants will then undergo protocol specific imaging to calculate the radiation dose to the kidneys, the bone marrow, and to the tumor lesions.
To continue on study and receive the combined therapy, a participant's imaging must demonstrate one of the following:
- At least one tumor that is positive for Azedra but negative for Lutathera in addition to Lutathera positive tumors, or,
- At least one tumor site where the calculated safe radiation dose to that tumor site is 25% higher using the combined therapy compared to Lutathera alone
Participants who do not meet this criteria are invited to participate in the comparator arm to receive standard Lutathera treatment as indicated by their physicians.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Combination Therapy
Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow.
The drug administration is individualized to each participant.
|
intravenous administration
Other Names:
intravenous administration
Other Names:
|
ACTIVE_COMPARATOR: Lutathera® only
Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
|
intravenous administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Determination of maximum tolerated radiation dose (MTD) to the kidneys
Time Frame: 9 months after initial treatment
|
MTD will be determined by incidence of renal AEs as characterized by type, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
|
9 months after initial treatment
|
Phase 1: Determination of maximum tolerated radiation dose (MTD) to the bone marrow.
Time Frame: 9 months
|
MTD will be determined by incidence of hematologic AEs as characterized by type, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
|
9 months
|
Phase 2: Objective Response Rate (ORR)
Time Frame: 6 months post-treatment
|
Objective response rate, measured using standardized RECIST criteria, is a reflection of complete tumor response and partial tumor response when obtained at 6 months and 12 months post-treatment.
|
6 months post-treatment
|
Phase 2: Objective Response Rate (ORR)
Time Frame: 12 months post-treatment
|
Objective response rate, measured using standardized RECIST criteria, is a reflection of complete tumor response and partial tumor response when obtained at 6 months and 12 months post-treatment.
|
12 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor size
Time Frame: 6 months post-treatment
|
Determine tumor size and response using RECIST 1.1 criteria in patients treated with the combined regimen
|
6 months post-treatment
|
Tumor size
Time Frame: 12 months post-treatment
|
Determine tumor size and response using RECIST 1.1 criteria in patients treated with the combined regimen
|
12 months post-treatment
|
Number of Treatment-Related Adverse Events
Time Frame: Up to 24 months post-treatment
|
Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (v5)
|
Up to 24 months post-treatment
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med. 2006 Apr;47(4):660-7.
- Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202005556
- P50CA174521 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Francesco De CobelliCompleted
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
Oslo University HospitalUniversity Hospital of North Norway; Haukeland University Hospital; St. Olavs...RecruitingPancreatic Neuroendocrine Tumors, WHO Grade I-IINorway
Clinical Trials on Lutathera
-
Ralph NULL SalloumChildren's Hospital Medical Center, CincinnatiRecruitingHigh Grade Glioma | Medulloblastoma | Meningioma | Anaplastic Ependymoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary... and other conditionsUnited States
-
Advanced Accelerator ApplicationsActive, not recruitingGastro-enteropancreatic Neuroendocrine TumorSpain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingProgressive Disease | Neuroendocrine Tumors | Intestinal Well Differentiated Endocrine TumorFrance
-
Imperial College LondonNot yet recruiting
-
King's College Hospital NHS TrustAdvanced Accelerator ApplicationsNot yet recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid Heart Disease
-
Advanced Accelerator ApplicationsActive, not recruitingGastroenteropancreatic Neuroendocrine TumorItaly
-
Novartis PharmaceuticalsActive, not recruitingSomatostatin Receptor-positive GEP-NETKorea, Republic of
-
Novartis PharmaceuticalsCompletedNeuroendocrine TumorUnited States
-
Erasmus Medical CenterRecruitingNeuroendocrine TumorsNetherlands
-
NYU Langone HealthRecruitingMeningiomaUnited States